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Background: We report updated progression-free survival (PFS) and overall survival (OS) data from a trial that
compared capecitabine plus oxaliplatin (CapeOX) versus S-1 plus oxaliplatin (SOX) for the first-line treatment of
metastatic colorectal cancer.
Methods: This trial was a randomized, two-armed, non-inferiority phase 3 comparison of CapeOX (capecitabine
1000 mg/m2 twice daily on days 1–14 and oxaliplatin 130 mg/m2 on day 1) versus SOX (S-1 40 mg/m2 twice daily
on days 1–14 and oxaliplatin 130 mg/m2 on day 1). The primary end point was to show non-inferiority of SOX
relative to CapeOX in terms of PFS. Thus, a follow-up exploratory analysis of PFS and OS was performed.
Results: The intention to treat (ITT) population was comprised of 340 patients (SOX arm: 168 and CapeOX arm:
172). The updated median PFS was 7.1 months (95% CI 6.4-8.0) in the SOX group and 6.3 months (95% CI 4.9-6.7) in
the CapeOX group (hazard ratio [HR], 0.83 [0.66-1.04], p = .10). The median OS was 19.0 months (95% CI 15.3-23.0) in
the SOX group and 18.4 months (95% CI 14.1-20.7) in the CapeOX group (HR, 0.86 [0.68-1.08], p = .19). Subgroup
analyses according to principal demographic factors such as sex, age, ECOG (Eastern Cooperative Oncology Group)
performance status, primary tumor location, measurability, previous adjuvant therapy, number of metastatic organs,
and liver metastases showed no interaction between any of these characteristics and the treatment.
Conclusions: Updated survival analysis shows that SOX is similar to CapeOX, confirming the initial PFS analysis.
Therefore, the SOX regimen could be an alternative first-line doublet chemotherapy strategy for patients with
metastatic colorectal cancer.
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Fluoropyrimidines (5FU) have remained the most com-
monly prescribed agents for gastrointestinal cancer, in-
cluding colorectal cancer (CRC). 5FU is administered as
a continuous infusion by a portable pump or by an
inserted chemo-port, methods that provide continuous
exposure and modest improvement in efficacy. However,
continuous infusion is inconvenient and unsafe [1,2].
Thus, the development of oral FU (capecitabine and S-1)
has opened new possibilities for the treatment of gastro-
intestinal tumors, especially gastric cancers [3-5]. For the
first-line treatment of patients with metastatic CRC, oxali-
platin plus either fluorouracil or capecitabine has been
one of the reference doublet cytotoxic chemotherapy
strategies [6,7]. S-1 is a novel oral FU consisting of a 5FU
prodrug, tegafur, the dihydropyrimidine dehydrogenase
inhibitor, 5-chloro-2, 4-dihydroxypyrimidine, and the
orotate phosphoribosyl transferase inhibitor, potassium
oxonate, which suppresses the gastrointestinal toxicity of
tegafur [8]. Although several trials have shown the feasibil-
ity and efficacy of S-1 plus oxaliplatin (SOX) as an upfront
chemotherapy for metastatic CRC [9,10], S-1 and capecit-
abine have not been directly compared when either is
combined with oxaliplatin. To address this dearth of
information, we conducted our initial randomized, non-
inferiority phase III trial of SOX versus capecitabine plus
oxaliplatin (CapeOX) for the first-line treatment of pa-
tients with metastatic colorectal cancer [11]. We found
the S-1 group to have nearly 2 months longer PFS than
the capecitabine group, suggesting that the SOX regimen
could be an alternative first-line doublet chemotherapy
strategy for patients with metastatic CRC. However, which
particular S-1s can be used as substitutes for capecitabine
may be controversial in CRC. Thus, we intend to update
the overall survival (OS) and progression free survival
(PFS) results, and we intend to conduct exploratory ana-
lyses to determine whether the effect of S-1 on these end
points appears to vary in selected patient groups.
Methods
Study design
This was a randomized, open-label, multicenter phase 3
study [11]. The institutional review boards of all partici-
pating institutions approved the study protocol. Written,
informed consent was required for participation.
To be eligible, patients with metastatic colorectal
cancer were required to have histologically confirmed
adenocarcinoma, measurable or assessable lesions, an
Eastern Cooperative Oncology Group (ECOG) performance
status (PS) of 0–2, no previous chemotherapy or immuno-
therapy in a metastatic setting, adequate hematological,
hepatic, and renal function, and be 18 years of age or
older. Adjuvant chemotherapy or radiotherapy was
permitted if it had been completed at least 6 monthsbefore enrollment. We randomly assigned eligible pa-
tients to either CapeOX or SOX in a one-to-one ratio.
Randomisation was done centrally with a computer-
generated sequence and a permutation block technique
that ensured equal distribution of patients on the basis
of primary tumor site (colon vs. rectum), history of
previous adjuvant or neoadjuvant treatment, and the
presence of measurable lesions.
Procedures
All treatment cycles were administered every three
weeks. We administered oral S-1 (40 mg/m2) twice a
day on days 1–14, oral capecitabine (1000 mg/m2) twice
a day on days 1–14, and oxaliplatin (130 mg/m2) on day
1 as a 2-h intravenous infusion. As many as nine cycles
of oxaliplatin-containing chemotherapy were provided,
except in instances of disease progression, unacceptable
toxicity, or patient refusal. Maintenance chemotherapy
with S-1 or capecitabine was permitted after discontinu-
ation of oxaliplatin. Treatment responses were assessed
every three cycles (9 weeks) during study treatments or
sooner if needed for documentation of disease progres-
sion. Objective tumor responses were independently
reviewed according to the Response Evaluation Criteria
In Solid Tumors (RECIST; version 1.0).
Statistical analyses
For the primary efficacy analysis, in which we aimed to
assess the non-inferiority of SOX to CapeOX in terms of
PFS (time to progression or death), we assessed all pa-
tients allocated to the treatment group (intention to
treat population), and we also did a per-protocol analysis
in those who received protocol treatments without
major violations. PFS at 15 months in both groups was
assumed to be 38%, and the low non-inferiority limit
was set as −13%, corresponding to a HR of 1.43. On the
basis of these conditions, 192 events were needed for a
one-sided type I error of 5% and a power of 80%.
Assuming a 10% loss, we needed 344 patients. Previous
reports were made at the August 31, 2011 cut-off date
for data collection. These updated data were collected at
the cut-off date of December 24, 2013. The survival data
were assessed with the Kaplan-Meier method. We esti-
mated the hazard ratio (HR) and corresponding 95% CI
using the Cox proportional hazard regression model.
Also, we analyzed post-progression survival (PPS; the
duration of survival after disease progression to study
medication) among two groups.
Results
Patients
Between May 14, 2008 and September 23, 2009, we en-
rolled 348 patients from 11 institutions. We randomly
assigned 340 patients who met the eligibility criteria to
Figure 1 CONSORT diagram.
Table 1 Baseline characteristics (intention to treat
population)
SOX (n = 168) CapeOX (n = 172)
Primary site
Colon 109 (65%) 108 (63%)
Rectum 59 (35%) 64 (37%)
Sex
Male 109 (65%) 102 (59%)
Female 59 (35%) 70 (41%)
Age
≤65 years 121 (72%) 126 (73%)
>65 years 47 (28%) 46 (27%)
ECOG performance status
0-1 164 (98%) 168 (98%)
2 4 (2%) 4 (2%)
Previous (neo)adjuvant therapy
Yes 37 (22%) 38 (22%)
No 131 (78%) 134 (78%)
Site of metastasis
Liver metastasis 105 (63%) 111 (65%)
Non-liver metastasis 63 (37%) 61 (35%)
Number of metastatic organs
One organ 65 (39%) 49 (29%)
Two organs 61 (36%) 70 (41%)
Three or more organs 42 (25%) 53 (31%)
Measurability
Measurable lesions 155 (92%) 155 (90%)
Assessable lesions only 13 (8%) 17 (10%)
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to the SOX group, and 172 were assigned to the CapeOX
group (Figure 1). This updated analysis used data collected
by December 24, 2013, by which time, 301 (SOX group:
150, CapeOX group: 151) PFS events, and 279 (134; SOX
group, 145; CapeOX group) OS events had occurred. In
the previous analysis, 207 (98; SOX group, 109; CapeOX
group) PFS events, and 179 (84; SOX group, 95; CapeOX
group) OS events had occurred. Of note, the baseline
characteristics were much the same between the two
groups (Table 1).
Progression-free survival (PFS) and post-progression
survival (PPS)
In the SOX group with media 17.91 follow-up, the median
PFS was 7.1 months (6.4-8.1), and the corresponding value
in the CapeOX group with median 16.41 follow-up was
6.3 months (4.9-6.7, intention to treat [ITT] population)
(Table 2 and Figure 2). The HR comparing PFS between
the two groups was 0.83 (95% CI 0.66-1.04, p = .10). For
the ITT population, the median post-progression survival
(PPS) was 9.3 months in the SOX group compared to 9.5
months in the CapeOX group, with a corresponding HR
of 0.97 (95% CI 0.76-1.23, p = .81) (Table 2 and Figure 2).
Overall survival (OS)
The OS data in the ITT population as of December 24,
2013 are shown in Table 2. The corresponding Kaplan-
Meier curves for OS are shown in Figure 3.
For the ITT population, median OS was 19.0 months
in the SOX group compared to 18.5 months in the
CapeOX group, with a corresponding HR of 0.86 (95%
CI 0.68-1.08).
Table 2 Survival outcomes
Intention to treat population Per-protocol population
SOX CapeOX Effect size (95% CI); p value SOX CapeOX Effect size (95% CI), p value
Number of patients 168 172 164 161
Median PFS 7.1 (6.4-8.1) 6.3 (4.9-6.7) 0.83 (0.66-1.04), p = .10 6.9 (6.4-7.9) 6.3 (5.2-6.7) 0.84 (0.67-1.06), p = .13
Median OS 19.0 (15.3-23.0) 18.5 (14.1-20.8) 0.86 (0.68-1.08), p = .19 19.1 (15.0-23.0) 17.6 (14.1-20.5) 0.85 (0.67-1.08), p = .17
Number of patients 150 151 147 145
Median PPS 9.3 (6.7-11.6) 9.5 (7.4-12.1) 0.97 (0.76-1.23), p = .81 9.3 (6.9-11.6) 9.6 (7.4-12.1) 0.96 (0.75-1.23), p = .75
Data are represented as n (%), time in months (95% CI) or effect size (95% CI). SOX, S-1 plus oxaliplatin; CapeOX, Capecitabine plus oxaliplatin; PFS, progression-free
survival; PPS, post-progression survival, OS = overall survival.
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OS and PFS in assigned patients were analyzed according
to sex, age, ECOG PS, primary tumor site, previous adju-
vant therapy, measurability, number of metastatic organs,
and liver metastasis. There was no interaction between
the treatment and any of these factors (Figure 4).
Discussion
The primary analysis of this study showed that SOX is
non-inferior to CapeOX in terms of PFS, OS, and response
rate as a first-line chemotherapy in patients with metastatic
colorectal cancer (CRC) [11]. To the best of our know-
ledge, this study is the first large, phase III clinical trial that
directly compares SOX with CapeOX in metastatic CRC.
This updated analysis also demonstrates that SOX and
CapeOX have statistically similar PFS and OS, confirming
the conclusion reached in our previous publication.
In this updated analysis, patients in the CapeOX group
had a PFS of 6.3 months and an OS of 18.5 months,
which are similar values to those reported in previous
trials [6,12-14]. Likewise, the SOX group in our analysis
showed favorable results, which are similar to values re-
corded for CapeOX or FU plus oxaliplatin plus Leucov-
orin (FOLFOX) treatment in previous studies [12-14].Figure 2 Kaplan-Meier curves of progression-free survival (PFS) (A) anBased on our updated analysis with a long-term follow-
up, no significant differences were observed in PFS and
OS between the SOX and CapeOX groups, which is
consistent with previous gastrointestinal cancer studies
[15-18]. In addition, a meta-analysis by Zhang et al. re-
ported that both the S-1 and capecitabine-based regimens
were equally active and well tolerated in patients with
gastric cancer and CRC [19].
In this updated analysis, we also investigated the post-
progression survival (PPS) for both treatment groups. In
cancer treatment, the goal is to prolong survival and/or
to improve the patient’s quality of life. In the era of
multiple lines of chemotherapy, therapeutic options have
been expanded, especially in CRC. In breast cancer, lung
cancer, and CRC, OS becomes more associated with PPS
than PFS [20-23]. In CRC, the association of PPS with
OS may be due to the increasing number of active com-
pounds available, or to the available second or third-line
therapies. In this analysis, there was no significant differ-
ence in PPS between the SOX and CapeOX groups
(Table 2). These findings suggest that effective treat-
ments, equal in quality, were provided to both groups
after the failure of the first-line therapy. The dose of S-1
in this study was 80 mg/m2 per day, which is higherd post-progression- survival (PPS) (B).
Figure 3 Kaplan-Meier curves of overall survival (OS).
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with oxaliplatin. As mentioned in a previously published
report, this dose finding explains the high frequency of
adverse events in SOX-treated patients. However, the
high frequency of adverse events in the SOX group
might not affect subsequent treatment strategies.Figure 4 Subgroup analysis of overall survival (A) and progression-freIn patients with metastatic CRC, the addition of beva-
cizumab to the first-line chemotherapy has improved
survival. Previous studies have shown that bevacizumab
plus FOLFOX, FOLFIRI (leucovorin, fluorouracil, and
irinotecan), or CapeOX improves PFS [12,14,24-26].
However, the role of bevacizumab with SOX has note survival (B) for the intention to treat population.
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bevacizumab plus SOX was non-inferior to bevacizumab
plus FOLFOX as a first-line treatment for metastatic
CRC with respect to PFS [27]. Thus, bevacizumab plus
SOX might be a possible option as a standard first-line
treatment, although S-1 and capecitabine have not been
directly compared when either is combined with bevaci-
zumab and oxaliplatin.
Our updated analysis confirms that a combination of S-1
and oxaliplatin can be considered as an alternative doublet
chemotherapy strategy to CapeOX. Further investigation is
needed to explore its potential when used together with
other targeted agents or as adjuvant chemotherapy.
Conclusion
Updated survival analysis shows that SOX is similar to
CapeOX, confirming the initial PFS analysis. Therefore,
the SOX regimen could be an alternative first-line doub-
let chemotherapy strategy for patients with metastatic
colorectal cancer.
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